UNSPSC 51184004: Glibenclamide or glyburide

This classification denotes a cation channel blocker and anti-diabetic agent with the molecular formula C23H28ClN3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SX6K58TVWC, chemically known as urea, 1-((p-(2-(chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexyl- but more generally known as glibenclamide, which bears US NIH Compound Identifier 3488.

UNSPSC 51184004 Glibenclamide or glyburide is a Commodity code covering a diabetes management pharmaceutical supplied through state and local healthcare systems and cooperative purchasing vehicles. State and local procurement under this code centers on generic pharmaceutical sourcing through multistate cooperative agreements, where jurisdictions leverage volume purchasing to procure branded and generic diabetes medications, including sulfonylurea agents like glibenclamide and glyburide, at negotiated rates. Issuing bodies are primarily state healthcare agencies and multistate cooperative purchasing alliances that serve participating state and local government facilities, health departments, and corrections systems. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary recent buyer in this space, issuing blanket RFPs for generic multi-source pharmaceuticals and OTC products that consolidate demand across member jurisdictions.

MMCAP's recent activity spans Minnesota and Oregon. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) posted January 20, 2026, with a response deadline of March 26, 2026, seeking multiple vendors to supply generic pharmaceuticals and OTC products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Evaluation is weighted heavily on price competitiveness (75 percent), with fixed pricing for the contract term (10 percent), compliance with administrative fee data format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must demonstrate cGMP certification, DSCSA compliance, and maintain contractual relationships with at least two of the three authorized wholesalers. Products must be available in the marketplace by May 15, 2026, with resulting contracts effective July 1, 2026 and a two-year initial term with optional extensions. Insurance requirements include commercial general liability of $5,000,000 per occurrence and professional liability of $2,000,000.